Noah Medical Raises $150M Series B to Scale Endoluminal Robotics Solutions

Noah Medical has raised $150 million in Series B funding. With participation from a number of well-known institutional and strategic investors, Noah Medical will use the funds to meet rising demand for the Galaxy System, its next-generation, integrated solution for navigated robotic bronchoscopy. The oversubscribed round included investments from Softbank Vision Fund, Prosperity7 Ventures, Tiger Global, Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, AME cloud ventures, as well as undisclosed strategic investors.

The announcement of this infusion of capital follows a series of recent milestone achievements for the Galaxy System™, which is designed to improve location accuracy and successful diagnosis of lung nodules using its proprietary TiLT+ Technology™. Already having received high marks from interventional pulmonologists who tested the system over the prior year, Noah Medical recently announced the platform received FDA clearance for commercial use in the United States and that it has initiated first-in-human trials at Macquarie University Hospital in Sydney, Australia.